According to Medicare Director Meena Seshamani, upcoming drug pricing negotiations will take the patient perspective and real-world evidence (RWE) into account. The agency wants to incorporate information about how high prices of key therapeutics impacts patients, as well as how the drugs are used and work in real-world settings.
According to Politico, “The top drug industry group PhRMA told POLITICO that it has no problems with the approach but is concerned about the lack of clarity in the guidance on the quality of data standards. Drugmakers also remain concerned about transparency in the process, which CMS has said will be confidential.”
To read more, click here.
(Source: Politico, June 6th, 2023)